Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/33766

Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population

Title:
Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population
Authors:
Fernandez-Diaz, Eva  
Perez-Vicente, Jose A.
VILLAVERDE GONZALEZ, RAMON  
Berenguer Ruiz, Leticia  
Candeliere Merlicco, Antonio  
Martinez-Navarro, Maria Luisa
Gracia Gil, Julia  
Romero-Sanchez, Carlos M.
Alfaro Sáez, Arantxa  
Diaz, Inmaculada
Gimenez‑Martinez, Juana
Mendez-Miralles, Maria Angeles
Millan-Pascual, Jorge
Jimenez-Pancho, Javier
Mola, Santiago  
Sempere, Angel P.
Editor:
Wiley Periodicals LLC
Department:
Departamentos de la UMH::Medicina Clínica
Issue Date:
2021
URI:
https://hdl.handle.net/11000/33766
Abstract:
Objective: Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are limited. The aim of this study was to evaluate the preliminary safety profile and effectiveness of ocrelizumab treatment for multiple sclerosis (MS) in a real-world clinical setting. Methods: We conducted a retrospective study including consecutive patients from nine public hospitals in south-eastern Spain who received ocrelizumab after it was approved. Results: A total of 228 MS patients were included (144 with relapsing–remitting MS [RRMS], 25 secondary progressive MS [SPMS], and 59 primary progressive MS [PPMS]). Median follow-up period was 12 months (range, 1-32). No evidence of disease activity (NEDA) status at year 1 was achieved in 91.2% of the relapsing MS (RMS) population, while disability progression was detected in 37.5% of the PPMS patients (median follow-up period, 19 months). The most common adverse events reported were infusion-related reactions and infections, with the most common infections being urinary tract infections followed by upper respiratory infections and COVID-19. Interpretation: The preliminary results in our real-world setting show that ocrelizumab presented excellent results in suppressing disease activity with a favorable and consistent safety profile.
Keywords/Subjects:
Esclerosis múltiple
ocrelizumab
Knowledge area:
CDU: Ciencias aplicadas: Medicina
Type of document:
application/pdf
Access rights:
info:eu-repo/semantics/openAccess
DOI:
https://doi.org/10.1002/acn3.51282
Appears in Collections:
Artículos Medicina Clínica



Creative Commons ???jsp.display-item.text9???